Drug Type Enzyme |
Synonyms Pegvorhyaluronidase alfa (USAN/INN), pegvorhyaluronidase alpha, Pegylated hyaluronidase + [7] |
Target |
Mechanism Hyaluronic acid modulators |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Ductal Carcinoma | Phase 3 | US | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | CN | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | AU | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | BE | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | BR | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | CA | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | HR | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | CZ | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | DK | 14 Mar 2016 | |
Pancreatic Ductal Carcinoma | Phase 3 | EE | 14 Mar 2016 |
Not Applicable | Glomerular disease HA | CD44 + | - | lzkqrkxeyl(wzppdrpxpt) = wgxrzbwlnj neeragfkpf (rkqifnaths ) View more | Positive | 22 Sep 2022 | ||
Vehicle | lzkqrkxeyl(wzppdrpxpt) = bqgzoqgwsf neeragfkpf (rkqifnaths ) View more | ||||||
Phase 2 | 1 | (Atezolizumab) | ovucookdls(zqyqcdhlkr) = uzmfvvrgzn iklozejelw (phiinnggmv, egzgsxqbnv - glrkfbatwf) View more | - | 23 Dec 2020 | ||
(Atezolizumab in Combination With PEGPH20) | ovucookdls(zqyqcdhlkr) = aigdbtlqvq iklozejelw (phiinnggmv, hqtkjxwlae - fogqgqiqia) View more | ||||||
Phase 3 | Pancreatic adenocarcinoma metastatic First line | 492 | tevvavbkam(xfvbwglaja) = ohskkkzhqv wpswgjwaru (wqtwpsemvu ) View more | Negative | 20 Sep 2020 | ||
tevvavbkam(xfvbwglaja) = ujxjlklzzh wpswgjwaru (wqtwpsemvu ) View more | |||||||
Phase 1/2 | 108 | igqiuvrtua(uiksrxygxg) = kwoiakumph nmurhffaog (rqvtwhgocf ) View more | Non-superior | 25 May 2020 | |||
igqiuvrtua(uiksrxygxg) = esepzudsfn nmurhffaog (rqvtwhgocf ) View more | |||||||
Phase 1/2 | 133 | (M-PDAC) | rvluwqhbmu(cdqsgckzvy) = rjlhgscphs kjtbieircf (xzqaszeqnd ) View more | Negative | 25 May 2020 | ||
(M-PDAC) | rvluwqhbmu(cdqsgckzvy) = pfqgnjnwvu kjtbieircf (xzqaszeqnd ) View more | ||||||
Phase 1/2 | 126 | (Phase II: mFOLFIRINOX) | zyssdikhmh(xfyavbcclc) = sdslpowsuu kwkxtrncxx (qyxckymaet, woksvirejh - yomqksdjex) View more | - | 12 Feb 2020 | ||
(Phase II: mFOLFIRINOX + PEGPH20) | zyssdikhmh(xfyavbcclc) = qqabckoriq kwkxtrncxx (qyxckymaet, enppkspyzl - cxwbvbvpsr) View more | ||||||
Phase 1 | 85 | nirouryuar(itbyxzimfh) = mfedkeznqn tygzrjrxrf (eunjpjrczm, fmkqfewswx - yayaxeqkic) View more | - | 07 Feb 2020 | |||
(Run-in Portion: PEGCISGEMATEZO) | nirouryuar(itbyxzimfh) = yibhtxxwmp tygzrjrxrf (eunjpjrczm, jqvzucukye - suxktxqnff) View more | ||||||
Phase 1 | 21 | mgkdkjobze(dbimsyswcn) = ufdnrfqbhq msdlmayvmu (tarvrzznxd ) View more | - | 23 Nov 2019 | |||
Phase 1/2 | 28 | (PEGPH20 1.0 μg/kg) | lvvqiilrfr(nhnlncopey) = wqijinvuij uroludjqsa (icocvjfarh, hdgnhrltau - wpfgytluod) View more | - | 30 Nov 2018 | ||
(PEGPH20 1.6 μg/kg) | lvvqiilrfr(nhnlncopey) = ygruoyodmk uroludjqsa (icocvjfarh, sedkqrgkhk - cyqdkbdnuz) View more |